Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$316.50 USD

316.50
623,669

+8.57 (2.78%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $316.68 +0.18 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

West Pharmaceutical Services (WST) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, West Pharmaceutical Services (WST) closed at $400.69, marking a -0.01% move from the previous day.

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

by Zacks Equity Research

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical Services (WST) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, West Pharmaceutical Services (WST) closed at $393.22, marking a +0.05% move from the previous day.

Here's Why You Should Add Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

West Pharmaceutical Services (WST) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, West Pharmaceutical Services (WST) closed at $378.36, marking a -1.35% move from the previous day.

SmileDirectClub (SDC) Moves up on New Strategic Actions

by Zacks Equity Research

SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain

by Zacks Equity Research

Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth

by Zacks Equity Research

Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.

Here's Why You Should Hold on to National Vision (EYE) for Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.

Here's Why You Should Invest in Abbott (ABT) Stock Right Now

by Zacks Equity Research

Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.

    Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?

    by Zacks Equity Research

    Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.

      Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal

      by Zacks Equity Research

      Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.

      Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass

      by Zacks Equity Research

      Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.

      Here's Why You Should Hold on to ResMed (RMD) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.

      Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

      by Zacks Equity Research

      Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.

      Edwards Lifesciences (EW) at 52-Week High: What's Driving It?

      by Zacks Equity Research

      Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).

      West Pharmaceutical Services (WST) Outpaces Stock Market Gains: What You Should Know

      by Zacks Equity Research

      West Pharmaceutical Services (WST) closed at $459.84 in the latest trading session, marking a +1.37% move from the prior day.